<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652404</url>
  </required_header>
  <id_info>
    <org_study_id>HN01</org_study_id>
    <nct_id>NCT01652404</nct_id>
  </id_info>
  <brief_title>PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial</brief_title>
  <acronym>ProShort-Ped</acronym>
  <official_title>PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunan Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to give conclusive evidence on whether serial PCT
      (Procalcitonin) measurements can facilitate individual decision-making and shorten antibiotic
      treatment duration in patients with sepsis in the pediatric ICU (Intensive Care Unit).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators aimed to design a multi-center trial addressing
      aforementioned flaws. The investigators will set stricter inclusion criteria, collect
      complete data on relapse or secondary infection, and include sufficient number of patients to
      show non-inferiority to conventional therapy by a delta margin of 10% [11]. The investigators
      aimed to give conclusive evidence on whether serial PCT measurements can facilitate
      individual decision-making and shorten antibiotic treatment duration in patients with sepsis
      in the pediatric ICU.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average antibiotics duration</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of antibiotics use in both arms</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>90 days</time_frame>
    <description>Efficacy endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of fever within 72 hours of antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score (Sequential Organ Failure Assessment score)</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection rate between 72-hours and 28 days post antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day readmission rate</measure>
    <time_frame>90 days</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Procalcitonin-guided treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The duration of antibiotics will be determined by the procalcitonin levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The duration of antibiotics will be determined by the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Procalcitonin-guided treatment</intervention_name>
    <description>The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.</description>
    <arm_group_label>Procalcitonin-guided treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>The antibiotics duration will be determined by treating physician.</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with laboratory- or image-confirmed severe infection at admission or during
        stay in pediatric ICU will be eligible for inclusion.

        * Definition of laboratory- or image-confirmed severe infection:

          -  Two or more of four signs of inflammation:

               -  Temperature &gt;38.3℃ or &lt;36℃

               -  Heart rate &gt; 90 beats/min

               -  Respiratory rate &gt;20 breaths/min or PaCO2 (Arterial pressure of carbon dioxide) &lt;
                  32 mmHg

               -  WBC (White Blood Cell count) &gt; 12,000 cells/mm3, &lt;4000 cells/mm3, or &gt;5%
                  band-form WBC

          -  Initial Procalcitonin &gt; 0.5 ng/mL

          -  Presence of either laboratory or image evidence of infection

          -  Laboratory evidence: Sign of inflammation in urine, CSF (Cerebrospinal Fluid),
             ascites, pleural effusion or local abscess

          -  Image evidence: Compatible findings on Chest X ray, ultrasound, CT (Computed
             Tomography), MR image (Magnetic Resonance Image)

        Exclusion Criteria:

          -  Age greater than 15 years or less than 1 month

          -  Known pregnancy

          -  Expected ICU stay less than 3 days

          -  Neutropenia: ANC (Absolute Neutrophil Count) &lt;500/mm3

          -  Specific infections for which long-term antibiotic treatment is strongly recommended:

               -  Lobar pneumonia or empyema

               -  Bacterial meningitis

               -  Osteomyelitis

               -  Infective endocarditis

               -  Local abscess

               -  Mediastinitin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi-Min Zhu, BSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hunan Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <phone>886972651951</phone>
    <email>cclee100@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi-Min Zhu, BSc</last_name>
    <phone>073185356850</phone>
    <email>csvzhuyimin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Children's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Min Zhu, BSc</last_name>
      <phone>073185386850</phone>
      <email>csvzhuyimin@163.com</email>
    </contact>
    <investigator>
      <last_name>Yi-Min Zhu, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev. 2003;(1):CD003966. Review.</citation>
    <PMID>12535494</PMID>
  </reference>
  <reference>
    <citation>Lee SL, Islam S, Cassidy LD, Abdullah F, Arca MJ; 2010 American Pediatric Surgical Association Outcomes and Clinical Trials Committee. Antibiotics and appendicitis in the pediatric population: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2010 Nov;45(11):2181-5. doi: 10.1016/j.jpedsurg.2010.06.038. Review.</citation>
    <PMID>21034941</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU</keyword>
  <keyword>sepsis</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>procalcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

